Boston Scientific products

Specialty Pharmaceuticals

Voraxaze

Voraxaze (glucarpidase) is commercially available in the US where it is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Voraxaze breaks down methotrexate into inactive metabolites which are then eliminated from the body by routes other than the kidney (primarily the liver). Voraxaze is the first and only drug available to reduce toxic plasma methotrexate levels.